Previous 10 |
HOLON, Israel , Oct. 24, 2018 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its third quarter 2018 financial results on Wednesday, November 7...
Compugen Ltd. (CGEN) Bristol-Myers Squibb Clinical Collaboration and Equity Investment Conference Call October 11, 2018 08:30 AM ET Executives Elana Holzman - Investor Relations and Corporate Communications Anat Cohen-Dayag - President and CEO Kirk Christoffersen - Senior Vice P...
SPEX +34% on merger agreement with CBM BioPharma. More news on: Spherix Incorporated, Compugen Ltd., Turtle Beach Corporation, Stocks on the move, , Top stock market news, Read more ...
Thinly traded micro cap Compugen (NASDAQ: CGEN ) is up 18% premarket on light volume on the heels of its announced collaboration with Bristol-Myers Squibb (NYSE: BMY ) evaluating the combination of COM701, an anti-PVRIG antibody, and Opdivo (nivolumab) in patients with advanced...
NEW YORK and HOLON, Israel , Oct. 11, 2018 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY) and Compugen (NASDAQ: CGEN) today announced the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Compugen's COM701, an invest...
HOLON, Israel , Sept. 20, 2018 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, was informed that Bayer AG dosed the first patient in the Phase 1 clinical trial of BAY 1905254, a firs...
News, Short Squeeze, Breakout and More Instantly...
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors PR Newswire FDA clearance triggers a $30 million milestone payment from Gilead Company on track to initiate a Phase 1 trial for COM503, a differentiated antibody approach to harne...
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 PR Newswire HOLON, Israel , July 23, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target ...
Compugen to Present at Upcoming Antibody Industrial Symposium PR Newswire HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, t...